{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:47:49Z","timestamp":1793407669216,"version":"4.5.0"},"reference-count":52,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":922,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1111\/ane.12106","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T16:25:31Z","timestamp":1361463931000},"page":"73-82","source":"Crossref","is-referenced-by-count":64,"title":["Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis"],"prefix":"10.1155","volume":"128","author":[{"given":"X.-W.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-M.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-F.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"10.1111\/ane.12106-BIB0001|ane12106-cit-0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0166-2236(03)00032-8","article-title":"Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders","volume":"26","author":"Mattson","year":"2003","journal-title":"Trends Neurosci"},{"key":"10.1111\/ane.12106-BIB0002|ane12106-cit-0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.advenzreg.2003.11.012","article-title":"Methylation demand and homocysteine metabolism","volume":"44","author":"Stead","year":"2004","journal-title":"Adv Enzyme Regul"},{"key":"10.1111\/ane.12106-BIB0003|ane12106-cit-0003","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0140-6736(05)65956-9","article-title":"Serum total homocysteine concentration and risk of stroke","volume":"348","author":"Perry","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/ane.12106-BIB0004|ane12106-cit-0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.18457","article-title":"Homocysteine as a risk factor for atherosclerosis","volume":"34","author":"Temple","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ane.12106-BIB0005|ane12106-cit-0005","first-page":"471","article-title":"Hyperhomocysteinemia: a new risk factor for degenerative diseases","volume":"48","author":"Herrmann","year":"2002","journal-title":"Clin Lab"},{"key":"10.1111\/ane.12106-BIB0006|ane12106-cit-0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neulet.2009.11.014","article-title":"Impaired transmethylation potential in Parkinson's disease patients treated with l-Dopa","volume":"468","author":"Bonis","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1111\/ane.12106-BIB0007|ane12106-cit-0007","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/01.wnl.0000183063.99107.5c","article-title":"Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease","volume":"65","author":"Irizarry","year":"2005","journal-title":"Neurology"},{"key":"10.1111\/ane.12106-BIB0008|ane12106-cit-0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12106-BIB0009|ane12106-cit-0009","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1111\/ane.12106-BIB0010|ane12106-cit-0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/ane.12106-BIB0011|ane12106-cit-0011","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1002\/sim.2889","article-title":"Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity","volume":"26","author":"Peters","year":"2007","journal-title":"Stat Med"},{"key":"10.1111\/ane.12106-BIB0012|ane12106-cit-0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","article-title":"Nigral endothelial dysfunction, homocysteine, and Parkinson's disease","volume":"354","author":"Muller","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/ane.12106-BIB0013|ane12106-cit-0013","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/ane.12106-BIB0014|ane12106-cit-0014","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","article-title":"Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease","volume":"47","author":"Blandini","year":"2001","journal-title":"Clin Chem"},{"key":"10.1111\/ane.12106-BIB0015|ane12106-cit-0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/jnnp.74.4.549","article-title":"Benefit of folic acid supplementation in parkinsonian patients treated with levodopa","volume":"74","author":"Muller","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12106-BIB0016|ane12106-cit-0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration","volume":"61","author":"Muller","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12106-BIB0017|ane12106-cit-0017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-7091-0579-5_2","article-title":"MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease","volume":"68","author":"Woitalla","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"10.1111\/ane.12106-BIB0018|ane12106-cit-0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jocn.2004.09.012","article-title":"Endothelial function markers in parkinsonian patients with hyperhomocysteinemia","volume":"12","author":"Bostantjopoulou","year":"2005","journal-title":"J Clin Neurosci"},{"key":"10.1111\/ane.12106-BIB0019|ane12106-cit-0019","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12106-BIB0020|ane12106-cit-0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","article-title":"Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients","volume":"11","author":"Valkovic","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12106-BIB0021|ane12106-cit-0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12106-BIB0022|ane12106-cit-0022","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.WNF.0000236763.16032.60","article-title":"Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications","volume":"29","author":"Hassin-Baer","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/ane.12106-BIB0023|ane12106-cit-0023","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1179\/016164106X110445","article-title":"Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations","volume":"28","author":"Ozer","year":"2006","journal-title":"Neurol Res"},{"key":"10.1111\/ane.12106-BIB0024|ane12106-cit-0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease","volume":"404","author":"Religa","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1111\/ane.12106-BIB0025|ane12106-cit-0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2006.05.040","article-title":"Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy","volume":"248","author":"Todorovic","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12106-BIB0026|ane12106-cit-0026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12017-007-8006-x","article-title":"Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients","volume":"9","author":"Caccamo","year":"2007","journal-title":"Neuromolecular Med"},{"key":"10.1111\/ane.12106-BIB0027|ane12106-cit-0027","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S1353-8020(08)70681-3","article-title":"2.269 Plasma homocysteine levels in idiopathic Parkinson's disease: role of idiopathic Parkinson's disease and levodopa treatment","volume":"13","author":"Ha","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12106-BIB0028|ane12106-cit-0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2008.10.005","article-title":"Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients","volume":"15","author":"Nevrly","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12106-BIB0029|ane12106-cit-0029","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2009.09.007","article-title":"Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients","volume":"287","author":"Yuan","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12106-BIB0030|ane12106-cit-0030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.22511","article-title":"Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia","volume":"24","author":"Zoccolella","year":"2009","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12106-BIB0031|ane12106-cit-0031","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12017-012-8174-1","article-title":"Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients","volume":"14","author":"Gorgone","year":"2012","journal-title":"Neuromolecular Med"},{"key":"10.1111\/ane.12106-BIB0032|ane12106-cit-0032","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12106-BIB0033|ane12106-cit-0033","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12106-BIB0034|ane12106-cit-0034","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson's disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"10.1111\/ane.12106-BIB0035|ane12106-cit-0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12106-BIB0036|ane12106-cit-0036","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.56.2.281","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"56","author":"Brattstrom","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/ane.12106-BIB0037|ane12106-cit-0037","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"key":"10.1111\/ane.12106-BIB0038|ane12106-cit-0038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","article-title":"Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats","volume":"20","author":"Miller","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/ane.12106-BIB0039|ane12106-cit-0039","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","article-title":"The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats","volume":"112","author":"Nissinen","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1111\/ane.12106-BIB0040|ane12106-cit-0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J Neurochem"},{"key":"10.1111\/ane.12106-BIB0041|ane12106-cit-0041","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-131-5-199909070-00006","article-title":"Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study","volume":"131","author":"Bostom","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1111\/ane.12106-BIB0042|ane12106-cit-0042","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12106-BIB0043|ane12106-cit-0043","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/17425255.2011.575779","article-title":"Motor complications, levodopa metabolism and progression of Parkinson's disease","volume":"7","author":"Muller","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/ane.12106-BIB0044|ane12106-cit-0044","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1056\/NEJM199905133401901","article-title":"The effect of folic acid fortification on plasma folate and total homocysteine concentrations","volume":"340","author":"Jacques","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12106-BIB0045|ane12106-cit-0045","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(06)70598-1","article-title":"Vitamin B12, folic acid, and the nervous system","volume":"5","author":"Reynolds","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12106-BIB0046|ane12106-cit-0046","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1468-1331.2009.02894.x","article-title":"Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients","volume":"17","author":"Belcastro","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12106-BIB0047|ane12106-cit-0047","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","article-title":"Homocysteine levels after acute levodopa intake in patients with Parkinson's disease","volume":"24","author":"Muller","year":"2009","journal-title":"Mov Disord"},{"key":"10.1111\/ane.12106-BIB0048|ane12106-cit-0048","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","article-title":"Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease","volume":"16","author":"Muller","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ane.12106-BIB0049|ane12106-cit-0049","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-011-0614-9","article-title":"Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa\/carbidopa gel","volume":"118","author":"Muller","year":"2011","journal-title":"J Neural Transm"},{"key":"10.1111\/ane.12106-BIB0050|ane12106-cit-0050","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1600-0404.2012.01689.x","article-title":"Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease","volume":"126","author":"Palhagen","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12106-BIB0051|ane12106-cit-0051","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"key":"10.1111\/ane.12106-BIB0052|ane12106-cit-0052","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/sim.1461","article-title":"Adjusting for publication bias in the presence of heterogeneity","volume":"22","author":"Terrin","year":"2003","journal-title":"Stat Med"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12106\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:46:40Z","timestamp":1671540400000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12106","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}